SinoFresh Healthcare CEO Reports Strong Growth Potential on European Mission

Mar 15, 2011, 16:00 ET from SinoFresh HealthCare, Inc.

VENICE, Fla., March 15, 2011 /PRNewswire/ -- SinoFresh® HealthCare, Inc., (Pink Sheets: SFSH) announced today that its CEO, David Olund, will remain in Europe this week to continue talks with a number of international distributors.

Mr. Olund embarked on a one week mission to Europe to meet with distributors interested in selling SinoFresh's patented Antiseptic Nasal and Sinus Care Spray across Europe and throughout Asia. The meetings, arranged with leading healthcare distribution companies, were initiated by the European and Asian firms for the purpose of introducing SinoFresh to these markets. This expansion of the sales base will serve to more than double the Company's prospective market and make SinoFresh available to more than 2 billion people globally.

The European talks are part of the Company's broader growth program which includes the recently signed distribution agreement with Cardinal Health and the inclusion of SinoFresh Antiseptic Nasal and Sinus Care Spray on major e-commerce websites. SinoFresh is also now available directly from the Company's website at

David R. Olund, CEO states, "The talks here are going extremely well. Not only have I had the opportunity to discuss significant sales growth with major distributors, but I also have additional meetings planned that were unexpected when I departed from Florida last week. This tremendous interest in our product has encouraged me to stay a bit longer to advance these talks even further. I am now more confident than ever that SinoFresh will soon be available to a broad, global market."

SinoFresh HealthCare, Inc. is a publicly traded company (Pink Sheets: SFSH) based in Venice, Florida, that manufactures and distributes nasal, oral and topical antiseptic germ-killing products. SinoFresh products are marketed and distributed globally through a network of strategic wholesale and retail partners. SinoFresh Healthcare, Inc's, premier product, SinoFresh Antiseptic Homeopathic Nasal spray has in laboratory tests shown effective antiseptic capability against a variety of pathogens such as MRSA, E-Coli, H1N1 and a broad range of other viruses, molds, fungi and bacteria.  

This press release includes forward-looking statements intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. Our forward-looking statements express our current expectations or forecasts of possible future results or events, including projections of future performance, statements of management's plans and objectives, future contracts, and forecasts of trends and other matters. Forward-looking statements speak only as of the date of this filing, and we undertake no obligation to update or revise such statements to reflect new circumstances or unanticipated events as they occur. You can identify these statements by the fact that they do not relate strictly to historic or current facts and often use words such as "anticipate", "estimate", "expect", "believe", "will likely result", "outlook", "project" and other words and expressions of similar meaning. No assurance can be given that the results in any forward-looking statements will be achieved and actual results could be affected by one or more factors, which could cause them to differ materially. For these statements, we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act.


SinoFresh HealthCare, Inc.

Investor Relations

941.375.8174 option 8

SOURCE SinoFresh HealthCare, Inc.